Bommarito Luisa, Zisa Giuliana, Riccobono Francesca, Villa Elisa, D'Antonio Cristian, Calamari Ambra M, Poppa Mariangela, Moschella Adele, Di Pietrantonj Carlo, Galimberti Maurizio
Allergology and Immunology Unit, Novara Hospital-Experimental Program Piemonte Allergy Network, Novara, Italy.
Allergy Asthma Proc. 2014 Jul-Aug;35(4):303-6. doi: 10.2500/aap.2014.35.3765.
Drug provocation tests (DPTs) are the gold standard in diagnosing nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity; however, only few data about follow-up of patients with negative DPTs are actually available. The aim of this study was to assess patients' behavior in taking NSAIDs again and to evaluate NSAID tolerability after negative allergological workup. This is a follow-up study involving patients evaluated for history of cutaneous reactions (urticaria and or angioedema) after NSAID intake and with negative DPTs with the suspected NSAID. Patients were asked during a phone interview about the intake of NSAIDs, tolerance, or reasons of avoidance. The negative predictive value (NPV) of NSAIDs DPTs was calculated. One hundred eleven of 142 patients were successfully contacted; 46/111 (41.44%) took the same NSAID previously tested with two adverse reactions reported (4.34%). Fifty-three of 111 (47.74%) patients did not take the same NSAID, but 34 of them took at least another strong cyclooxygenase (COX) 1 inhibitor, with 1 adverse reaction (2.94%) and 19 of them took only weak COX-1 inhibitors. Twelve of 111 patients (10.8%) did not take any NSAID. Reasons for drug avoidance were mainly fear of reactions (70.8%) and no need (29.2%). NPV, overall, was 96.97% (95% confidence interval, 91-99%). Although NSAID hypersensitivity diagnosis was ruled out by oral provocation test, the majority of patients with a history of urticaria/angioedema avoided the intake of the tested NSAIDs for fear of new reactions, particularly when strong COX-1 inhibitor NSAIDs were involved. The high NPV value of DPT resulting from this study should reassure NSAID intake.
药物激发试验(DPTs)是诊断非甾体抗炎药(NSAID)超敏反应的金标准;然而,关于药物激发试验结果为阴性的患者随访的实际数据却很少。本研究的目的是评估患者再次服用NSAIDs的行为,并评估变应性检查结果为阴性后的NSAID耐受性。这是一项随访研究,纳入了因服用NSAIDs后有皮肤反应(荨麻疹和/或血管性水肿)病史且对可疑NSAIDs的药物激发试验结果为阴性的患者。通过电话访谈询问患者服用NSAIDs的情况、耐受性或避免服用的原因。计算了NSAIDs药物激发试验的阴性预测值(NPV)。142例患者中有111例成功联系;111例中的46例(41.44%)服用了之前进行过试验的相同NSAID,报告了2例不良反应(4.34%)。111例患者中有53例(47.74%)未服用相同的NSAID,但其中34例至少服用了另一种强效环氧化酶(COX)-1抑制剂,出现1例不良反应(2.94%),19例仅服用了弱效COX-1抑制剂。111例患者中有12例(10.8%)未服用任何NSAID。避免用药的主要原因是担心出现反应(70.8%)和无需用药(29.2%)。总体而言,NPV为96.97%(95%置信区间,91-99%)。尽管口服激发试验排除了NSAID超敏反应的诊断,但大多数有荨麻疹/血管性水肿病史的患者因担心出现新的反应而避免服用试验用的NSAIDs,尤其是涉及强效COX-1抑制剂NSAIDs时。本研究得出的药物激发试验的高NPV值应能让人们放心服用NSAIDs。